ClinicalTrials.gov record
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
ClinicalTrials.gov ID: NCT01682863
Public ClinicalTrials.gov record NCT01682863. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Study identification
- NCT ID
- NCT01682863
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Enrollment
- 614 participants
Conditions and interventions
Conditions
Interventions
- QVA149 Drug
- QAB149 Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 40 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2012
- Primary completion
- May 31, 2014
- Completion
- May 31, 2014
- Last update posted
- Mar 29, 2016
2012 – 2014
United States locations
- U.S. sites
- 47
- U.S. states
- 26
- U.S. cities
- 46
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis Investigative Site | Vestavia Hills | Alabama | 35216 | — |
| Novartis Investigative Site | Huntington Beach | California | 92647 | — |
| Novartis Investigative Site | Lakewood | California | 90712-151 | — |
| Novartis Investigative Site | Los Angeles | California | 90048 | — |
| Novartis Investigative Site | Orange | California | 92868 | — |
| Novartis Investigative Site | Stockton | California | 95207 | — |
| Novartis Investigative Site | Walnut Creek | California | 94598 | — |
| Novartis Investigative Site | Boulder | Colorado | 80304 | — |
| Novartis Investigative Site | Honolulu | Hawaii | 96814 | — |
| Novartis Investigative Site | Lombard | Illinois | 60148 | — |
| Novartis Investigative Site | O'Fallon | Illinois | 62269 | — |
| Novartis Investigative Site | Peoria | Illinois | 61602 | — |
| Novartis Investigative Site | Evansville | Indiana | 47712 | — |
| Novartis Investigative Site | Ames | Iowa | 50010 | — |
| Novartis Investigative Site | Iowa City | Iowa | 52240 | — |
| Novartis Investigative Site | Waterloo | Iowa | 50702 | — |
| Novartis Investigative Site | Bowling Green | Kentucky | 42101 | — |
| Novartis Investigative Site | New Orleans | Louisiana | 70115 | — |
| Novartis Investigative Site | Slidell | Louisiana | 70458 | — |
| Novartis Investigative Site | Bangor | Maine | 04401 | — |
| Novartis Investigative Site | Baltimore | Maryland | 21224 | — |
| Novartis Investigative Site | Livonia | Michigan | 48152 | — |
| Novartis Investigative Site | Minneapolis | Minnesota | 55407 | — |
| Novartis Investigative Site | Jackson | Mississippi | 39209 | — |
| Novartis Investigative Site | Picayune | Mississippi | 39466 | — |
| Novartis Investigative Site | Saint Charles | Missouri | 63301 | — |
| Novartis Investigative Site | Missoula | Montana | 59804 | — |
| Novartis Investigative Site | Lincoln | Nebraska | 68506 | — |
| Novartis Investigative Site | Omaha | Nebraska | 68131 | — |
| Novartis Investigative Site | Henderson | Nevada | 89014 | — |
| Novartis Investigative Site | Las Vegas | Nevada | 89119 | — |
| Novartis Investigative Site | Rochester | New York | 14618 | — |
| Novartis Investigative Site | Dayton | Ohio | 45459 | — |
| Novartis Investigative Site | Dublin | Ohio | 43016 | — |
| Novartis Investigative Site | Oklahoma City | Oklahoma | 73103 | — |
| Novartis Investigative Site | Oklahoma City | Oklahoma | 73112 | — |
| Novartis Investigative Site | Eugene | Oregon | 97404 | — |
| Novartis Investigative Site | Medford | Oregon | 97504-8741 | — |
| Novartis Investigative Site | Spartanburg | South Carolina | 29303 | — |
| Novartis Investigative Site | Knoxville | Tennessee | 37912 | — |
| Novartis Investigative Site | Corsicana | Texas | 75110 | — |
| Novartis Investigative Site | Fort Worth | Texas | 76104 | — |
| Novartis Investigative Site | Lufkin | Texas | 75904 | — |
| Novartis Investigative Site | McKinney | Texas | 75069 | — |
| Novartis Investigative Site | Abingdon | Virginia | 24210 | — |
| Novartis Investigative Site | Midlothian | Virginia | 23114 | — |
| Novartis Investigative Site | Newport News | Virginia | 23606 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 39 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01682863, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 29, 2016 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01682863 live on ClinicalTrials.gov.